Hindustan Syringes and Medical Devices to invest over Rs 100 crore to expand syringe production

Published On 2021-04-05 06:31 GMT | Update On 2021-11-23 11:34 GMT

New Delhi: With the surge in Covid cases amid the rising demand for syringes during the ongoing vaccination drive in India, Hindustan Syringes and Medical Devices (HMD) on Sunday said that the company will invest over Rs 100 crore to expand its production capacity from 2.5 billion syringes to over 3 billion.

Rajiv Nath, Managing Director, HMD told that the company not only needs to invest in production lines of syringes-moulds, moulding machines, printing and assembly packaging, etc. but also in needle assembly, needles point grinding, recruiting workers and training them.

"Our current production capacity is over 2.7 billion syringes per annum of disposable and auto-disable syringes are approximately 90 lakhs daily. And we are investing over Rs 100 crore to ramp up capacity from 2.5 billion syringes to over 3 billion by next quarter," Nath informed.

The medical syringe major recently received an order for the supply of 265 million auto disable syringes from the Union government. The company has allocated two-thirds of its production capacity for the government orders, and the balance for global UN customers.

HMD ships out 0.1 ml and 0.5 ml auto disposable Kojak syringes for global vaccination projects in the developing world, for yellow fever, measles, hepatitis B and others.

This is in addition to Covid-19 vaccination requirements of 0.3 ml for Pfizer's vaccines or 0.5 ml auto-disable Kojak for AstraZeneca/Serum Institute of India (SII) or Bharat Biotech vaccines.

According to Nath, HMD has been practicing the government's 'Atmanirbhar Bharat' initiative for decades by making their components.

"We do share the Prime Minister's vision and quest for an Atmanirbhar Bharat. It is in our DNA," Nath said.

"It is another matter that government policies in the last 10 years favour imports of medical devices and components. So it's no more a competitive advantage to produce these components in India," he added.

The company said that it is also facing few challenges in the process of production and supply due to the pandemic.

"Due to Covid-19 pandemic, the delivery of moulds and machines from Indian and international suppliers is getting delayed by 1 to 3 months and with severe travel restrictions in many countries, we have to install the machines on our own as foreign technicians are not available which further delays commercial utilisation too," Nath noted.

The company has received orders for 240 million Kojak syringes for COVAX via UNICEF and 79 million for Brazil for Dispovan syringes via PAHO.

"We had also shipped 140 million Kojak syringes to Covid-19 Vaccine Global Access (COVAX) last December. We have recently sold 15 million syringes to the Japanese government. In total, we serve over 120 countries worldwide," he said.

Earlier, Nath had told IANS that over 440 million Kojak syringes will be supplied to India's massive vaccination drive by September, including 177 million by April this year, alongside the supplies of Dispovan syringes to the private hospitals and vaccination clinics.

Read also: HMD to produce 177.6 million auto-disable syringes for Govt by March 2021

Article Source : IANS

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Hindustan Syringes and Medical Devices to invest over Rs 100 crore to expand syringe production

Similar News

One-shot Dengue vaccine 'DengiAll' completes 70% enrolment of participants in Phase III trial: Centre

Sun Pharma Gets Relief As Delhi HC Bars Use of BERIVITAL, BEZOLIC, DOZE-30 For Trademark Infringement

Senores Pharma appoints Sanjay Moralwar as Head of IT

CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver, Mandates Phase-IV Trial in India

SIL declares profit from operations growth as +6% vs previous year

Novartis Told to Revise Protocol, Justify Sample Size in ITU512 Clinical Trial Proposal

Health Ministry Notifies Cosmetics Rules 2025, Empowers States To Suspend Licences

Biodeal Told To Justify Novel Delivery Claim In NPPA Exemption Plea For Midazolam Nasal Spray